A clinical trial of MK-4605 in healthy participants (MK-4605-001)

2026-525627-24-00 Protocol MK-4605-001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 13 May 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol MK-4605-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 16
Countries 1
Sites 1

Dementia

Key facts

Sponsor
Merck Sharp & Dohme LLC
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
13 May 2026 → ongoing
Decision date (initial)
2026-05-06
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2026-525627-24-00
WHO UTN
U1111-1335-2973

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Dementia

VersionLevelCodeTermSystem organ class
20.0 PT 10012267 Dementia 100000004852

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Merck Sharp & Dohme LLC

Sponsor organisation
Merck Sharp & Dohme LLC
Address
126 East Lincoln Avenue, P. O. Box 2000 P. O. Box 2000
City
Rahway
Postcode
07065-4607
Country
United States

Scientific contact point

Organisation
Merck Sharp & Dohme LLC
Contact name
Alejandro Ramirez

Public contact point

Organisation
Merck Sharp & Dohme LLC
Contact name
Alejandro Ramirez

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ongoing, recruiting 16 1
Rest of world 0

Investigational sites

Belgium

1 site · Ongoing, recruiting
Universitair Ziekenhuis Gent
DRUG, Corneel Heymanslaan 10, 9000, Gent

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2026-05-13 2026-05-20

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-03-30 Belgium Acceptable with conditions
2026-05-06
2026-05-06